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REVIEW
Abstract: Overactive bladder (OAB) is a common problem presented to by physicians.
Standard treatment with antimuscarinic medication is directed at suppressing involuntary
detrusor contractions by blocking the binding of acetylcholine to muscarinic receptors in the
bladder. Oxybutynin chloride is the first of several antimuscarinic medications to be marketed
for OAB. Although efficacious for treating OAB symptoms, the side effects and suboptimal
dosing regimen decrease its utility. To improve patient compliance and tolerability, alternative
delivery systems for oxybutynin have subsequently been developed and include a once-daily
formulation and a transdermal system. The currently available formulations of oxybutynin
are the subject of this review.
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Introduction
Overactive bladder (OAB) is defined by the International Continence Society as a
syndrome associated with symptoms of urgency, with or without urge incontinence,
usually with frequency and nocturia, in the absence of infection or other obvious
pathology (Abrams et al 2002). The prevalence of continent and incontinent OAB in
the US is estimated to be 16.6%, affecting approximately 33 million men and women
(Stewart et al 2003). The high prevalence of urinary incontinence and OAB translates
to an estimated annual economic cost in US of $19.5 billion for urinary incontinence
and $12.6 billion for OAB (Hu et al 2004). In addition, indirect costs are incurred as
up to 65% of patients with OAB may have a reduced ability to perform daily tasks
(Rovner 2004). Although OAB has a significant negative impact on health-related
quality of life, mental health, and quality of sleep, the majority of OAB patients do
not seek treatment for their condition (Stewart et al 2002; Van der Vaart et al 2002).
Antimuscarinic agents, with the advent of immediate-release oxybutynin (OXY-
IR), have been the mainstay of treatment for OAB for the past 30 years. Although
many patients respond favorably to antimuscarinic agents, only a small percentage
of patients achieve total dryness (Appell et al 2001). Additionally, because muscarinic
receptors are found elsewhere in the body, nontissue-specific antimuscarinic agents
result in significant systemic side effects (Lai et al 2002; Dmochowski and Appell
2003). The combination of intolerable side effects, expense, and an often incomplete
improvement, result in a mediocre-at-best rate of patient compliance with
antimuscarinic medications. In one representative study involving patients taking
OXY-IR, adherence dropped from 91% at 3 months to 18% at 1 year (Echols et al
2000). These shortcomings have prompted the development of several new delivery
systems of oxybutynin: an extended-release formulation (OXY-ER), and a transdermal
system (OXY-TDS), as well as several other different antimuscarinic agents.
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Oxybutynin immediate-release
Oxybutynin chloride is a well established antimuscarinic
drug that has long been recognized for its efficacy in the
treatment of OAB symptoms. It remains the gold standard
with which newer agents are compared once efficacy over
placebo has been established. Oxybutynin is a tertiary amine
that has anticholinergic, spasmolytic, and local anesthetic
properties (Yarker et al 1995). It acts as a competitive
antagonist of acetylcholine at postganglionic muscarinic
receptors on the detrusor muscle of the bladder, resulting in
relaxation of the smooth muscle (OMNP 2003). Oxybutynin
has higher affinity for M1 and M3 receptor subtypes than
for other muscarinic subtypes. Also, it has a 10-fold greater
selectivity for M3 over M2 receptors (Noronha-Blob and
Kachur 1991; Nilvebrant et al 1997). Oxybutynin is a chiral
compound, and its anticholinergic effects are primarily
attributed to the (R) enantiomer (Noronha-Blob and Kachur
1991). As a spasmolytic, it has a nonstereoselective relaxant
effect on the smooth muscle of the bladder, although in vitro
studies suggest the spasmolytic effects are about 500 times
weaker than the antimuscarinic effects (Kachur et al 1988).
The contribution of the local anesthetic effects following
oral administration has yet to be determined.
Oxybutynin in the immediate-release form (OXY-IR) is
rapidly absorbed from the gut, with the mean tmax in the
range of 0.5–1 hour. OXY-IR then undergoes extensive
upper gastrointestinal and first-pass hepatic metabolism via
the CYP3A4 enzyme, which is part of the cytochrome
P-450 system, into multiple metabolites. Many of the other
available antimuscarinic medications are also metabolized
by the cytochrome P450 enzyme system, most commonly
involving enzymes CYP2D6 and CYP3A4 (Guay 2003).
With any of these medications there is a risk for drug–drug
interactions, resulting in either reduced (enzyme induction)
or increased (enzyme inhibition, substrate competition)
plasma concentration of either the antimuscarinic and/or
interacting drug. Coadministration of oxybutynin with a
potent CYP3A4 inhibitor such as itraconazole results in
increased mean oxybutynin plasma concentrations (Lukkari
et al 1997). No interaction appears to exist when oxybutynin
and oral contraceptives are coadministered (Guay 2003).
Less than 0.1% of the administered OXY-IR is excreted
unchanged in the urine (OMNP 2003). Studies evaluating
the pharmacokinetics of intravesical OXY-IR have
determined that significant systemic absorption occurs
following this route of administration; however, the drug/
metabolite ratio is increased after intravesical instillation
and its elimination is relatively protracted (Lehtoranta et al
2002).
The primary metabolite of oxybutynin, N-desethyl-
oxybutynin (DEO), has pharmacologic properties similar
to those of the parent compound. In vitro studies involving
both DEO and OXY-IR have demonstrated equivalent
activity in antagonizing detrusor contractions, suggesting
that a proportion of the therapeutic efficacy is likely
attributable to DEO. Higher affinity for the metabolite
relative to the parent compound has been noted in the parotid
gland, and DEO has therefore been implicated as the major
cause of the troublesome side effect of dry mouth (Waldeck
et al 1997).
The most frequently reported adverse effects related to
oxybutynin and all other antimuscarinic agents are due to
the anticholinergic actions of the drugs. These include dry
mouth, constipation, diarrhea, impaired urination,
somnolence, blurry vision, dizziness, nervousness, and
nausea. The frequency and severity of the side effects are
dose dependent (Comer and Goa 2000). Both oxybutynin
and DEO are highly lipophilic compounds: a property that
allows them to be well absorbed, but also allows them to
cross the blood–brain barrier and potentially cause central
nervous system (CNS) effects. The high lipophilicity,
neutrality, and small molecular size of oxybutynin may allow
it to more readily cross the blood–brain barrier and skin
(discussed below) relative to other antimuscarinic agents
(Scheife and Takeda 2005). Contraindications to oxybutynin
include urinary retention, severely decreased gastric motility
conditions, and untreated narrow-angle glaucoma (OMNP
2003).
Oxybutynin extended-release
Designed to allow for once daily dosing and decrease
adverse side effects, OXY-ER was approved by the US Food
and Drug Administration (FDA) in 1999. OXY-ER uses an
osmotic system (OROS®) to deliver oxybutynin chloride to
the gastrointestinal (GI) tract over a 24-hour period (ALZA
2004). This eliminates the serum concentration fluctuations
that contribute to the intolerable side effects associated with
OXY-IR (Preik et al 2004). OROS consists of a semi-
permeable membrane-enclosed bilayer core containing
oxybutynin chloride in one layer and osmotic agents in the
other layer. Once in the GI tract, water enters the capsule
and the oxybutynin forms a suspension. The expanding
osmotic layer then pushes the oxybutynin suspension out
of the capsule through a tiny laser-drilled hole in the capsuleTherapeutics and Clinical Risk Management 2006:2(1) 21
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membrane (Comer and Goa 2000; ALZA 2004). Oxybutynin
is then released continuously throughout the entire GI tract,
but primarily in the colon. OXY-ER reaches the colon
approximately 3–5 hours after oral administration (Sathyan
et al 2001). Because the CYP3A4 enzyme is located in
higher concentrations in the upper small intestine relative
to the lower GI tract, the amount of first-pass metabolism
and resulting DEO is reduced. This is reflected by a higher
mean bioavailability (153%) for oxybutynin and a lower
bioavailability (69%) for DEO following OXY-ER
administration compared with OXY-IR (Gupta and Sathyan
1999). Fluctuations in oxybutynin plasma concentration are
also minimized by the OROS system. Following oral
administration of OXY-ER, the plasma concentration
gradually increases for 4–6 hours, and then stabilizes for
the duration of the 24-hour dosage interval. Tmax is about
11–13 hours following a single dose (Siddiqui et al 2004).
Oxybutynin transdermal
An oxybutynin transdermal delivery system (OXY-TDS)
was approved by the FDA in 2003. OXY-TDS offers a twice-
weekly dosing regimen and the potential for improved
patient compliance and tolerability. The lipophilic quality
of oxybutynin allows for it to be adequately absorbed
trandermally. OXY-TDS utilizes a transdermal matrix
system that is composed of three layers. The first layer is a
thin flexible polyester–ethylene-vinyl acetate film that forms
a protective barrier. The second layer is an acrylic adhesive
that contains oxybutynin and triacetin, a skin permeation
enhancer that temporarily changes the characteristics of the
stratum corneum to allow diffusion of the oxybutynin from
the transdermal system through the skin. The third layer
consists of siliconized polyester strips that are peeled off
and discarded prior to use by the patient (WP 2003).
The transdermal delivery system bypasses the first-pass
metabolism that occurs in the GI tract and the liver.
Relatively small amounts of the CYP3A4 are found in the
skin, therefore limiting the presystemic metabolism, and
reducing the plasma concentration of DEO. There is an
absence of high peak concentrations and low metabolite
levels with OXY-TDS. Minimal fluctuations in plasma
concentration of oxybutynin are observed throughout the
96-hour wear period of the transdermal system. A steady state
concentration was achieved during the second application
(Zobrist et al 2003). Bioequivalent oxybutynin absorptions
resulted from buttock and hip applications. Stereoselective
metabolism was evident following OXY-TDS administration
with slightly lower plasma concentrations of the
R-enantiomers of oxybutynin and DEO (Zobrist et al 2001).
Currently, the only size patch commercially available is
the 3.9 mg/day patch. There is a size restriction based upon
the fact that 1 mg of oxybutynin to be delivered daily for up
to four days requires 1 cm
2 of patch. The patch may be cut
and remain intact. This has allowed dose escalation studies
to be performed using doses of 5.2 mg/day and 7.8 mg/day.
There have been no reports on the correlation between
efficacy or adverse events upon increasing the dose of OXY-
TDS. Furthermore, there has not been a rigorously
established conversion factor between oral and transdermal
dosing of oxybutynin.
Comparative studies
Clinical practice and the literature support the efficacy of
oxybutynin for the treatment of OAB. Numerous studies
exist in the literature comparing OXY-IR to placebo,
tolterodine, propantheline, propiverine, trospium,
darifenacin, the extended-release formulation of tolterodine
(TOL-LA), OXY-ER, and OXY-TDS (Riva and Casolati
1984; Tapp et al 1990; Thuroff et al 1991; Madersbacher et
al 1995, 1999; Abrams et al 1998; Drutz et al 1999; Appell
et al 2001; Halaska et al 2003; Homma et al 2003; Chapple
and Abrams 2005). Compared with placebo, OXY-IR
reduces urinary frequency by about 50% and urge
incontinence episodes by up to 70%, but the prevalence of
dry mouth varies between 12%–70%, depending on dosage
(Douchamps et al 1988). Although most patients respond
favorably to antimuscarinic medications such as OXY-IR,
smaller percentages achieve total dryness. In general, the
new formulations of oxybutynin and other antimuscarinic
agents offer patients efficacy roughly equivalent to that of
OXY-IR, and the advantages of the newer formulations lie
in improved dosing schedules and side effect profile
(Lawrence et al 2000; Appell et al 2001; Diokno et al 2003).
Several randomized, double-blind trials comparing
OXY-ER and OXY-IR have demonstrated that they are
similarly effective in relieving symptoms of OAB (Anderson
et al 1999; Versi et al 2000; Barkin et al 2004). Urge urinary
incontinence episodes, micturition frequency, and total
continence rates were similarly improved; however, OXY-
ER resulted in better tolerability (Anderson et al 1999).
Another randomized, double-blind, crossover study
comparing OXY-ER (10 mg once daily) and OXY-IR (5 mg
twice daily) established that OXY-ER was associated with
57% less side effects relative to OXY-IR (Birns et al 2000).Therapeutics and Clinical Risk Management 2006:2(1) 22
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OXY-ER was compared with tolterodine in a
randomized, double-blind study referred to as the OBJECT
(Overactive bladder: judging effective control and treatment)
trial. In terms of the number of episodes of urge
incontinence, total incontinence, and micturition frequency,
OXY-ER was found to be more effective than immediate-
release tolterodine (TOL-IR). Rates of dry mouth and other
adverse events were similar (Appell et al 2001).
Subsequently, with the development of TOL-LA, the
OPERA (Overactive bladder: performance of extended
release agents) trial was designed as a head-to-head
comparative study between OXY-ER and TOL-LA. This
study randomized 790 women with 21–60 urge urinary
incontinence episodes per week and 10 or more voids per
24 hrs to receive either OXY-ER 10 mg/day or TOL-LA
4 mg/day for 12 weeks. The primary end point was urge
urinary incontinence episodes. Both antimuscarinic agents
showed similar reductions in weekly urge urinary
incontinence and total incontinence episodes. OXY-ER
participants had a greater decrease in micturition frequency
and a higher proportion of participants who reported total
dryness in the last week of the study when compared with
the TOL-LA group (23.0% vs 16.8%, respectively, p = 0.03).
Dry mouth was the most common adverse effect in both
groups; it was more common with OXY-ER group relative
to the TOL-LA group (29.7% vs 22.3%, respectively,
p = 0.02). This problem was generally mild and was the
reason for discontinuation of the medication for only a few
patients (OXY-ER = 7; TOL-LA = 4). Other adverse events
were rare in both groups, with no serious adverse events
being attributed to either drug in the study (Diokno et al
2003). A one-year open-label trial of OXY-ER found that
60% of patients remained on OXY-ER (dose of 15 mg or
less) at 12 months. This is much higher than the continuation
rate reported in the literature for OXY-IR, which is only
18%–22% of patients continuing the medication at 6 months
(Kelleher et al 1997; Appell et al 2000; Lawrence et al 2000).
The efficacy and safety of OXY-TDS in patients with
urge urinary incontinence has been demonstrated in several
studies. In a phase three study involving 520 patients,
utilizing doses ranging from 1.3 mg/day to 3.9 mg/day, OXY-
TDS at 3.9 mg/day significantly reduced the number of
weekly incontinence episodes, reduced average daily urinary
frequency, increased average voided volume, and improved
quality of life relative to placebo. OXY-TDS was well
tolerated, with the most common adverse effect being
application site pruritus (10.8%–16.8%). The incidence of
dry mouth with OXY-TDS was similar to placebo (OXY-
TDS = 7%; placebo = 8.3%, p = 0.98) (Dmochowski et al
2002).
OXY-TDS has also been compared with OXY-IR in a
randomized double-blind dose titration study. Both OXY-
TDS and OXY-IR demonstrated a similar decrease in daily
incontinent episodes (OXY-TDS = 66%; OXY-OR = 72%,
p = 0.39); however, significantly fewer patients complained
of dry mouth in the OXY-TDS group (OXY-TDS = 38%,
OXY-IR = 94%, p < 0.001). Similar improvement in
urodynamic parameters was also demonstrated between the
two groups. Ninety percent of patients in the OXY-TDS
group had no or mild skin erythema (Davila et al 2001).
In a third study, OXY-TDS was compared with both
placebo and TOL-ER. TOL-ER was associated with a
significantly higher rate of antimuscarinic adverse events
relative to both OXY-TDS and placebo. The primary adverse
event for OXY-TDS was application site reaction pruritis
(14%) and erythema in (8.3%). These application site
reactions were severe enough to result in nearly 10% of
patients withdrawing from the study (Dmochowski et al
2003).
The side effect of xerostomia has been further evaluated
in studies that have evaluated saliva output as a surrogate
measure for dry mouth. In a crossover study comparing
placebo, OXY-ER (10 mg), TOL-IR (2 mg), and OXY-IR
(5 mg), salivary output was measured at baseline and at
numerous points following dosing. All three active
treatments resulted in decreased salivary output, however
OXY-ER and TOL-IR had significantly greater output
relative to OXY-IR (Chancellor et al 2001). More recently,
OXY-TDS (3.9 mg/day) and OXY-ER (10 mg/day) were
compared, correlating salivary output and plasma
concentrations of oxybutynin and DEO with symptomatic
dry mouth. Relative to OXY-ER, blood samples indicated
that OXY-TDS resulted in greater systemic availability and
minimal metabolism to DEO. Mean plasma concentrations
of oxybutynin were less variable in the OXY-TDS group.
The decreased plasma concentration of DEO corresponded
with greater salivary output and less complaints of dry mouth
in the OXY-TDS group compared with OXY-ER (Appell et
al 2003).
While most studies have focused on the symptom of dry
mouth as the main tolerability end point, it is also important
to consider other potential adverse effects. CNS safety is
important to consider when treating patients for OAB,
especially in the elderly. Both OXY-IR and DEO are both
highly lipophilic compounds which aid in absorption from
the GI tract, skin, or bladder, but also potentially allow forTherapeutics and Clinical Risk Management 2006:2(1) 23
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penetration into the CNS. In a randomized controlled dose-
titration trial involving OXY-IR and OXY-ER, there were
no significant differences in incidences of somnolence,
dizziness, or nervousness (Anderson et al 1999). In the
OBJECT trial which compared OXY-ER and TOL-IR, there
were similar rates on CNS adverse events between the
groups (Appell et al 2001). More recently, in a subanalysis
of the OPERA study, OXY-ER and TOL-ER were compared
and found to have a similarly low incidence of CNS adverse
effects (OXY-ER = 9% vs TOL-LA = 8%, p = 0.8), most of
which were mild or moderate in severity. No serious adverse
events were reported in either group. The incidence of
adverse CNS events was highest in the first 14 days of
treatment, demonstrating a trend toward increased tolerance
with time for both drugs (Chu et al 2005). Another study
comparing quantitative electroencephalography (qEEG)
effects of OXY-IR (20 mg), TOL-IR (2 mg), and trospium
chloride (45 mg), found that only OXY-IR produced
significant power reductions in the middle-frequency bands
(p < 0.01) (Todorova et al 2001). Although CNS
concentrations of the drugs and metabolites were not
measured, this may indicate that oxybutynin and/or DEO
more readily penetrate the blood-brain barrier due to their
high lipophilicity, neutrality, and small molecular size
relative to other antimuscarinic agents (Scheife and Takeda
2005).
Ocular side effects were targeted in another randomized
trial between OXY-IR (5 mg thrice daily) and TOL-ER (2 mg
twice daily). Following 4 weeks of treatment, OXY-IR
significantly decreased the accommodation amplitude,
whereas this effect was not noted following TOL-ER. Both
drugs caused a shorter tear film break-up time that could
potentially cause problems for patients with dry eyes (Altan-
Yaycioglu et al 2005).
Conclusion
Compared with OXY-IR, the more recently developed
delivery systems of oxybutynin, OXY-ER and OXY-TDS,
offer improved tolerability and dosing options for patients.
While these agents are often touted for causing less dry
mouth, these newer medications are currently more
expensive for patients, while being no more efficacious in
treating OAB symptoms. These issues are often reflected in
lower than expected patient compliance rates. Clearly there
is still a need for the development of other pharmacological
agents that prove to be more effective in helping patients
achieve total dryness and/or alleviation of OAB symptoms,
while having a favorable side effect profile and acceptable
dosing regimen.
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